Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels.

L Ferraro, M C Tomasini, T Cassano, B W Bebe, A Siniscalchi, W T O'Connor, Pamela Magee, S Tanganelli, V Cuomo, T Antonelli

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)

Abstract

The effects of the cannabinoid receptor agonist WIN 55,212-2 (0.1-5 mg/kg i.p.) on endogenous extracellular gamma-aminobutyric acid (GABA) levels in the cerebral cortex of the awake rat was investigated by using microdialysis. WIN 55,212-2 (1 and 5 mg/kg i.p.) was associated with a concentration-dependent decrease in dialysate GABA levels (-16% +/- 4% and -26% +/- 4% of basal values, respectively). The WIN 55,212-2 (5 mg/kg i.p.) induced-inhibition was counteracted by a dose (0.1 mg/kg i.p.) of the CB(1) receptor antagonist SR141716A, which by itself was without effect on cortical GABA levels. These findings suggest that cannabinoids decrease cortical GABA levels in vivo, an action that might underlie some of the cognitive and behavioral effects of acute exposure to marijuana.
Original languageEnglish
Pages (from-to)298-302
JournalJournal of Neuroscience Research
Volume66
Issue number2
Publication statusPublished (in print/issue) - 2001

Fingerprint

Dive into the research topics of 'Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels.'. Together they form a unique fingerprint.

Cite this